Human Immunodeficiency Virus (Hiv) Therapeutics Market Worth Will Be $15 billion in Sales by 2023
Human Immunodeficiency Virus (Hiv)
Therapeutics Market Worth Will Be $15
billion in Sales by 2023
The global HIV therapeutics market was worth approximately $14 billion in 2013, and it is expected to
rise a total of $15 billion in sales by 2023, at a Compound Annual Growth Rate (CAGR) of 0.9%. These
sales are expected to come predominantly from the US market, as financial austerity measures remain a
primary barrier to the growth of the HIV market in the other countries covered in this report.
The global HIV therapeutics Market & Forecasts to 2023 report provides a comprehensive analysis of the
current state of the market and likely future evolution over the next 5 years. This 461-page report with
174 Tables provides a complete analysis of Human Immunodeficiency Virus (Hiv) Therapeutics Market.
Browse Detailed Toc, Tables, Figures, Charts and Companies Mentioned in Human Immunodeficiency
Virus Market Analysis Report at –
Human immunodeficiency virus (HIV) is a retrovirus that infects the cells of the immune system,
destroying or impairing their function. As the infection progresses, the immune system becomes
increasingly weaker, making the infected person more susceptible to other infections. Since the first
anti-HIV drug, GlaxoSmithKline’s (GSK’s) Retrovir (azidothymidine), was approved in 1987, major
improvements have been made in the field of antiretroviral therapy (ART). This rapid progress has been
headlined by the emergence of once-daily, single-tablet regimens (STRs) such as Gilead Science's Atripla
(efavirenz/emtricitabine/tenofovir disoproxil fumarate [TDF]), which offer patients an unparalleled level
Ask for Discount on United Kingdom Trauma Fixation Market Research Report at –
+1 408 520 9750
global HIV marketplace - which, for the purposes of this report, comprises nine major pharmaceutical
markets (US, France, Germany, Italy, Spain, UK, Japan, Brazil, China) - to experience modest growth
during the forecast period. This growth will be driven primarily by the highly anticipated arrivals of novel
integrase inhibitor- (INI-) and protease inhibitor- (PI-) based STRs, which include ViiV Healthcare’s
Triumeq (dolutegravir/abacavir/lamivudine), Gilead’s Quad 2
(elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate [TAF]), and Gilead’s and Janssen’s
darunavir/cobicistat/emtricitabine/TAF. Nevertheless, looming patent expiries of high-grossing branded
drugs in the US, 5EU (France, Germany, Italy, Spain, UK), and Japan, along with compulsory licensing and
generic erosion in Brazil and China, are expected to curtail market growth.
Request sample PDF of this report at - http://www.absolutereports.com/enquiry/requestsample/10077324
Key Questions Answered in This Report:
- How will the HIV market landscape in the 9MM (US, France, Germany, Italy, Spain, UK, Japan, Brazil,
China) change from 2013-2023?
- What are the most promising late-stage pipeline drugs in HIV?
- How do the clinical and commercial attributes of late-stage pipeline therapies compare with one
another, and against existing treatment options?
- What are the unmet needs in HIV treatment management?
- What drivers and barriers will affect HIV therapeutics sales in the 9MM over the forecast period?
About Absolute Report:
Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and
taking visionary decisions based on facts and figures derived from in depth market research. We are one
of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of
Mr. Ameya Pingaley
+1-408 520 9750
Email – [email protected]
+1 408 520 9750